Inconsistent Results With Different Secondary Reflex Assays for ResolvingHER2Status

An alternative and sensitive method based on LCM and Q-PCR for HER2 testing in breast cancer

(2017) Bogdan Fetica et al.   Cancer Biomarkers

Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer

(2016) Tse Hui Lim et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Change in Pattern ofHER2Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines

(2016) Mithun Vinod Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the 2013 ASCO/CAPHER2Guideline Updates at an Academic Medical Center That Performs PrimaryHER2FISH Testing

(2015) Kristen E. Muller et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The New Equivocal

(2015) Thomas H. Long et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number

(2015) Min Hye Jang et al.   BREAST CANCER RESEARCH AND TREATMENT

Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR

(2015) Vladimira Koudelakova et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data

(2015) Oliver C Stoss et al.   MODERN PATHOLOGY

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience

(2015) Zsuzsanna Varga et al.   PLoS One

New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers

(2015) N. Tchrakian et al.   VIRCHOWS ARCHIV

Gene Status in HER2 Equivocal Breast Carcinomas: Impact of Distinct Recommendations and Contribution of a Polymerase Chain Reaction-Based Method

(2014) A. Sapino et al.   ONCOLOGIST

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

(2013) Aron Goldhirsch et al.   LANCET

HER2Gene Amplification in Breast Cancer

(2012) Jane Starczynski et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study

(2011) David J. Dabbs et al.   JOURNAL OF CLINICAL ONCOLOGY

Determining TrueHER2Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2Targeted Therapy

(2011) Chun Hing Tse et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 genetic heterogeneity in breast carcinoma

(2011) C. Ohlschlegel et al.   JOURNAL OF CLINICAL PATHOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity

(2010) Shelly Gunn et al.   BMC CANCER

Real-Time RT-PCR Analysis for Evaluating the Her2/neu Status in Breast Cancer

(2010) M. Cuadros et al.   PATHOBIOLOGY

Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification

(2009) Cathy B. Moelans et al.   BREAST CANCER RESEARCH AND TREATMENT

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescencein situhybridization and microarray-based CGH analysis

(2009) Caterina Marchiò et al.   JOURNAL OF PATHOLOGY

Quantitative PCR and HER2 Testing in Breast Cancer

(2008) Massimo Barberis et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Real Time RT-PCR Approach for the Evaluation of ERBB2 Overexpression in Breast Cancer Archival Samples: A Comparative Study With FISH, SISH, and Immunohistochemistry

(2008) Elisa Capizzi et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Monoplex LightCycler Polymerase Chain Reaction Quantitation of the HER2 Gene for Quality Assurance of HER2/neu Testing by Immunohistochemistry and Fluorescence In Situ Hybridization

(2008) Lester J. Layfield et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY